1397 ATG 027 a first in class B7 H3 PD L1 bispecific antibody shows potent T cell activation capability and in vivo anti tumor efficacy

MLA

Hui Yuwen, et al. “1397 ATG 027 a First in Class B7 H3 PD L1 Bispecific Antibody Shows Potent T Cell Activation Capability and in Vivo Anti Tumor Efficacy.” Regular and Young Investigator Award Abstracts, Nov. 2022. EBSCOhost, https://doi.org/10.1136/jitc-2022-sitc2022.1397.

APA

Hui Yuwen, Tengteng Li, Yijing Ren, Linjie Tian, Jay Mei, Bo Shan, & Bing Hou. (2022). 1397 ATG 027 a first in class B7 H3 PD L1 bispecific antibody shows potent T cell activation capability and in vivo anti tumor efficacy. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2022-sitc2022.1397

Chicago

Hui Yuwen, Tengteng Li, Yijing Ren, Linjie Tian, Jay Mei, Bo Shan, and Bing Hou. 2022. “1397 ATG 027 a First in Class B7 H3 PD L1 Bispecific Antibody Shows Potent T Cell Activation Capability and in Vivo Anti Tumor Efficacy.” Regular and Young Investigator Award Abstracts, November. doi:10.1136/jitc-2022-sitc2022.1397.